Friday 6 November 2026 Export AZR’s income statement to Excel — free account

Azora Therapeutics, Inc.

AZR Healthcare Biotechnology

EPS: −150.0%
Free cash flow: −263.7%

Quarter to June 2026, against a year earlier

Insider buying

3.82 0.23 −5.68%

Follow AZR

Alert me

Market cap: $9.7M
P/E: 0.0×
Fwd P/E: —
Dividend yield: —
F-score: n/a
Altman Z: n/a
Beneish M: n/a
Dividend safety: n/a

Overview

Insider Decisions last twelve months

Bought, $m 0.11

Trades a month
	Jan 26			Apr 26			Jul 26			Oct 26
Buy	—	—	—	—	—	—	1	2	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 48.51%

Capital & Financial Ratios $m

Size

Market Cap 9.74

Revenue ttm —

Net income ttm (57.80)

Free cash flow ttm (11.13)

Net debt Q (28.71)

Valuation

P/E 0.00

Forward P/E —

Price / sales 0.00

Forward P/S Powerpack

Price / FCF 0.00

Price / book 0.00

Financial health

Current ratio Q 5.63

Debt / equity Q 0.00

Interest coverage Q (133.13)

Growth

Revenue growth Q —

Operating income growth Q −2,664.35%

EPS, this year +59.23%

EPS, next year A +87.62%

Revenue, next year A —

EPS, past 5 yrs —

EPS, next 5 yrs A +58.58%

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

Dividends

Yield: —
Annual rate: —
Payout ratio: —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	3	4	6	29
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	3	4	6	29

	2023	2024	2025	Q'26
Payables	0	0	1	3
ST’ Debt	—	—	—	—
Other	—	—	—	—
	1	1	1	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	—	—
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	5.77%	17.21%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY25 Estimate −2.25 Actual −2.00

−14.07 −10.66 −7.25 −3.84 −0.43

Q4 FY24 Beat +5.75

Q1 FY25 Beat +4.00

Q2 FY25 Beat +1.00

Q3 FY25 Beat +0.25

Earnings per share against the consensus, by quarter
Quarter	Estimate	Reported	Result
Q4 FY24	−9.50	−3.75	Beat by 5.75
Q1 FY25	−12.50	−8.50	Beat by 4.00
Q2 FY25	−5.50	−4.50	Beat by 1.00
Q3 FY25	−2.25	−2.00	Beat by 0.25

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.48)	(11.25)	—	—	—
’25	(8.50)	(4.50)	(2.00)	(1.81)	(11.93)
’24	(54.75)	(14.75)	(9.50)	(8.04)	(68.00)
’23	(68.75)	24.00	(29.50)	(20.60)	(90.00)
’22	(81.25)	(100.00)	(75.00)	(68.75)	(318.75)
’21	(187.50)	(156.25)	(137.50)	(175.00)	(650.00)
’20	(137.50)	(100.00)	(150.00)	(150.00)	(543.75)

Fiscal quarters ending in the months shown.

Revenue $m

	Year

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(6)	—	—	—
’25	(2)	(2)	(2)	(1)	(6)
’24	(2)	(2)	(2)	(1)	(7)
’23	(2)	(2)	(1)	(1)	(7)
’22	(2)	(4)	(3)	(2)	(11)
’21	(3)	(3)	(4)	(2)	(12)
’20	(2)	(1)	(2)	(3)	(8)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(6)	—	—	—
’25	(2)	(2)	(2)	(1)	(6)
’24	(2)	(2)	(2)	(1)	(7)
’23	(2)	(2)	(1)	(1)	(7)
’22	(2)	(4)	(3)	(2)	(11)
’21	(3)	(3)	(4)	(2)	(12)
’20	(2)	(1)	(2)	(3)	(8)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	TTM Jun ’26	Trend	10 yrs	2026e	2027e	2028e	Next 3/yr
													Ten-year view		Analyst estimates Powerpack
Income, $m
Income, $m	Revenue	—	—	—	—	—	—	—	—	—	—	—		—	—	—	—	—
	Gross margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—	—	—	0.00		0.0 pt	Powerpack Azora Therapeutics, Inc.’s next three years, line by line See the consensus for every other line: earnings, margins, cash flow, valuation and returns. Unlock estimates Try Powerpack free for 7 days, then $99 / year ($8.25 a month). Cancel any time. Also in Powerpack: every quarter, Excel exports, API & MCP access. Compare plans
	EBT	0	(1)	(12)	(9)	(11)	(20)	(11)	(7)	(13)	(8)	(58)		+38.7%
	EBT margin, %	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		0.0 pt
	Net income	0	(1)	(12)	(9)	(11)	(19)	(11)	(7)	(13)	(8)	(58)		+38.7%
Per share, $
Per share, $	Revenue	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		n/m
	Earnings	(80.61)	(218.19)	(1,525.00)	(543.75)	(543.75)	(650.00)	(318.75)	(90.00)	(68.00)	(11.93)	(16.54)		(19.1%)
	Cash flow	(52.77)	(95.17)	(328.74)	(401.18)	(383.58)	(402.34)	(278.95)	(119.42)	(35.66)	(9.71)	(2.41)		(17.1%)
	Capex	0.00	0.00	0.00	0.00	0.00	(2.18)	0.00	0.00	0.00	0.22	0.00		n/m
	Free cash flow	(52.77)	(95.17)	(328.74)	(401.18)	(383.58)	(404.51)	(278.95)	(119.42)	(35.66)	(9.49)	(2.41)		(17.4%)
	Book value	(19.90)	(191.85)	584.38	451.94	200.31	118.11	81.71	71.64	20.96	7.89	(8.30)		n/m
	Shares, m	0	0	0	0	0	0	0	0	0	1	2		+71.5%
Valuation, ×
Valuation, ×	P/E	—	—	—	—	—	—	—	—	—	—	0		—
	P/S	—	—	—	—	—	—	—	—	—	—	0		—
	P/B	—	—	—	—	—	—	—	—	—	—	0		—
	EV/Sales	—	—	—	—	—	—	—	—	—	—	0		—
	EV/FCF	—	—	—	—	—	—	—	—	—	—	0		—
Cash, $m
Cash, $m	Operating cash flow	0	0	(2)	(6)	(8)	(12)	(11)	(7)	(7)	(6)	(11)		+42.1%
	Capex	—	—	—	—	—	0	—	—	—	0	0		n/m
	Free cash flow	0	0	(2)	(6)	(8)	(12)	(11)	(7)	(7)	(6)	(11)		+41.8%
Balance, $m
Balance, $m	Working capital	0	(1)	4	7	4	4	3	3	3	5	24		n/m
	Net debt	0	0	(4)	(7)	(4)	(6)	(4)	(3)	(4)	(6)	(29)		+59.5%
	Shareholders’ equity	0	(1)	4	7	4	4	3	4	4	5	(38)		n/m
Returns, %
Returns, %	ROA	(451.83)	(1,225.27)	(491.42)	(138.81)	(165.41)	(299.59)	(192.79)	(97.87)	(269.87)	(136.16)	(322.10)		+315.7 pt
	ROIC	0.00	0.00	(763.06)	(1,417.62)	0.00	0.00	0.00	(342.64)	(1,630.29)	0.00	0.00		0.0 pt
	ROE	76.32	206.97	(675.52)	(148.36)	(195.80)	(518.38)	(375.32)	(139.22)	(323.80)	(170.73)	352.60		(247.0) pt
People
People	Employees	—	3	6	4	9	21	4	7	7	6	—		+9.1%
	Revenue/emp, $m	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	—		n/m

Negative figures in brackets.

estimates

All 10 years →

Fundamentals updated 26 Oct 2026

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
PASG Passage Bio, Inc.	$11.1M	— (loss-making)	—	—	n/m	−59.81% (below 0%: shrinking)	0.00%	0.00%	Compare
LSTA Lisata Therapeutics, Inc.	$10.7M	— (loss-making)	— (loss-making)	−98.30% (below 0%: shrinking)	n/m	+33.04% (above 0%: growing)	100.00%	0.00%	Compare
GDTC CytoMed Therapeutics Limited	$10.4M	— (loss-making)	— (loss-making)	—	n/m	−27.39% (below 0%: shrinking)	0.00%	—	Compare
BIVI BioVie Inc.	$10.3M	— (loss-making)	—	—	n/m	+26.50% (above 0%: growing)	0.00%	0.00%	Compare
PTN Palatin Technologies, Inc.	$10.2M	12.2×	0.2×	−14.06% (below 0%: shrinking)	n/m	+34.21% (above 0%: growing)	100.00%	(1,469.35%)	Compare
INTS Intensity Therapeutics Inc.	$10.1M	— (loss-making)	—	—	n/m	+4.72% (above 0%: growing)	0.00%	0.00%	Compare
AZR Azora Therapeutics, Inc.	$9.7M	— (loss-making)	—	—	n/m	−263.66% (below 0%: shrinking)	0.00%	0.00%
GTBP GT Biopharma, Inc.	$9.4M	0.8×	—	−100.00% (below 0%: shrinking)	n/m	−41.34% (below 0%: shrinking)	0.00%	0.00%	Compare
PHIO Phio Pharmaceuticals Corp.	$9.3M	— (loss-making)	— (loss-making)	−8.70% (below 0%: shrinking)	n/m	−58.67% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$10.2M	—	—	−56.18%	—	−11.33%	0.00%	0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 24 August 2026

Chief executive’s pay

Year	Total pay	Actually paid	$100 invested
2025	890.65k	600.17k	4.09
2024	976.34k	823.53k	18.79
2023	801.62k	575.60k	34.60

Ownership

Directors and executive officers, together 8.00%

Matthew Davidson, Ph.D. (Chief Development Officer and Director) 14.80%

Coastlands Capital LP 14.20%

Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement